Pharmaceutical Raw Materials
Veterinary API
Antiallergic Drugs
Hormones and Endocrine Drugs
Drug Metabolism
Pharmaceutical Intermediates
Synthetic Anti Infective Drugs
Specialty Drugs
Vitamins and Minerals Medicines
Feed Drug Additive
Antineoplastic Agents
Nervous System Drugs
Respiratory Drugs
Diagnostic Agents
Anti Stress Drugs
Antipyretic Analgesics
Antiparasitic Drugs
Circulatory System Drugs
Biochemicals
Blood System Drugs
Immune System Medication
Pharmaceutical Excipients
Fluid, Electrolyte, and Acid-Base Balance
Urinary System Drugs
Antibiotics
Anesthetic Agents
Inhibitors
Other Chemical Drugs
Digestive System Drugs
CAS:107007-99-8
Molecular Formula:C18H25ClN4O
Alias
More Information
1-Methyl-N-[(3-Endo)-9-Methyl-9-Azabicyclo[3.3.1]Non-3-Yl]-1H-Indazole-3-Carboxamide; 1-Methyl-N-[(1S,5R)-9-Methyl-9-Azabicyclo[3.3.1]Nonan-3-Yl]Indazole-3-Carboxamide,Hydrochloride; 1-Methyl-N-(9-Methyl-9-Azabicyclo(3.3.1)Non-3-Yl)-1H-Indazole-3-Carboxamid; Endo-Monohydrochlorid; 1-Methylindazole-3-Carboxylic acid; Midehydrochloride; 1-Methyl-N-[(3-Endo)-9-Methyl-9-Azabicyclo[3.3.1]Non-3-Yl]-1H-Indazole-3-Carboxamide Hydrochloride; 1-Methyl-N-(9-Methyl-9-Azabicyclo[3.3.1]Nonan-3-Yl)-1H-Isoindole-3-Carboxamide Hydrochloride
Brief Introduction
Granisetron hydrochloride is a highly selective 5-HT3 receptor antagonist, which has good preventive and therapeutic effects on nausea and vomiting caused by radiotherapy, chemotherapy and surgery. Radiotherapy, chemotherapy and surgery can cause the release of 5-HT from the intestinal chromaffin cells. 5-HT can activate the 5-HT3 receptor of the central or vagus nerve and cause vomiting reflex. The mechanism of controlling nausea and vomiting is to inhibit the occurrence of nausea and vomiting by antagonizing 5-HT3 receptors in central chemosensory area and peripheral vagus nerve endings. It has high selectivity and no side effects such as extrapyramidal reaction and excessive sedation.
Suppliers
View More Vendors (3） >
CAS:122111-03-9
Molecular Formula:C9H12ClF2N3O4
Alias
More Information
2'-Deoxy-2',2'-Difluorocytidine; Gemcitabine Hcl(Tabines); 2’,2’-Difluorodeoxycytidinemonohydrochloride; 2’-Deoxy-2’,2’-Difluorocytidinemonohydrochloride; 2’-Deoxy-2’,2’-Difluoro-Cytidinmonohydrochloride; Gemzar; Ly188011; Ly188011 Hydrochloride; 2',2'-Difluoro-2'-Deoxycytidine
Brief Introduction
Gemcitabine hydrochloride is a synthetic new type of two fluoronucleoside antitumor drug developed by Eli Lilly. It was approved in 1995 in South Africa, Sweden, Holland, Australia and other countries. In 1996, the US Food and Drug Administration approved the first line treatment for non-small cell lung cancer and pancreatic cancer. Gemcitabine hydrochloride, a nucleoside homologue, is a cell cycle specific antitumor drug. It mainly kills cells in S phase (DNA synthesis) and blocks the transition of cell proliferation from G1 to S phase. Gemcitabine is suitable for the treatment of advanced or metastatic pancreatic cancer and locally advanced or metastatic non-small cell lung cancer, advanced and non-small cell lung cancer, pancreatic cancer, bladder cancer, breast cancer and other solid tumors.
Suppliers
View More Vendors (3） >
CAS:184475-35-2
Molecular Formula:C22H24ClFN4O3
Alias
More Information
Iressa; N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)Quinazolin-4-Amine; Irressat; N-(3-Chloro-4-Fluorophenyl)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)Quinazolin-4-Amine
Brief Introduction
Gefitinib is a quinazoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It inhibits the autophosphorylation of tyrosine kinase domain in EGFR cells by competitive binding to ATP and blocks the transmission of downstream signals, so as to inhibit tumor angiogenesis, cell proliferation, invasion and metastasis and promote apoptosis.
Suppliers
View More Vendors (3） >
CAS:220127-57-1
Molecular Formula:C30H35N7O4S
Alias
More Information
4-[(4-Methyl-1-Piperazinyl)Methyl]-N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-Benzamide Monomethanesulfonate; 4-[(4-Methylpiperazin-1-Yl)Methyl]-N-[4-Methyl-3-[(4-Pyridin-3-Ylpyrimidin-2-Yl)Amino]Phenyl]Benzamide Methanesulfonate
Brief Introduction
This product is an anti-tumor drug.
Suppliers
View More Vendors (3） >
CAS:320-67-2
Molecular Formula:C8H12N4O5
Alias
More Information
Vidaza; Ladakamycin; 5-Azacitidine; Azacitidine; 5-Ac; 5-Azac; Azgr; 5 Azc; [14C]-Azacitidine; 5-Azcr; 5-Ac-15N4; 5'-Azacytidine; Mylosar; 1,3,5-Triazine-2(1H)-One, 4-Amino-1-α-D-Ribofuranosyl-
Brief Introduction
Antimetabolic drugs. The main indication is acute myeloid leukemia which is ineffective to conventional treatment. It is also used for breast cancer, melanoma, intestinal cancer and so on. The main manifestations of toxicity were leucopenia, thrombocytopenia and anemia. Nausea and vomiting are common adverse reactions. Symptoms can be improved by continuous infusion for a long time, or antiemetic agents can be used 24 to 48 hours before treatment. Other toxic effects were diarrhea, neuromuscular disorders, fever, hypotension and rash. The preparation is freshly prepared 3-4h before use.
Suppliers
View More Vendors (3） >
Chuangxin Biotech
99
/
Food Grade
25kg
/
Fibre Drum
Inquiry (
10
/ 10
)
Clear All
Sign In
Error!